Previous 10 | Next 10 |
Amneal Pharmaceuticals (NYSE:AMRX) has received Abbreviated New Drug Application (ANDA) approval from the FDA for difluprednate ophthalmic emulsion 0.05%, which is the generic version of Durezol and is used in the treatment of inflammation and pain associated with ocular surgery. According to...
- Represents the latest generic ophthalmic product approval for Amneal Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food a...
Image source: The Motley Fool. Amneal Pharmaceuticals, inc (NYSE: AMRX) Q3 2021 Earnings Call Nov 3, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Amneal Pharmaceuticals, inc (AMRX) Q3 2021 Earnings Call Transcrip...
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2021 Earnings Conference Call Nov 03, 2021 08:30 AM ET Company Participants Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Conference Cal...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Amneal Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation
Amneal Pharmaceuticals (NYSE:AMRX): Q3 Non-GAAP EPS of $0.21 beats by $0.01; GAAP EPS of -$0.03 misses by $0.11. Revenue of $529M (+1.9% Y/Y) misses by $15.08M. Press Release Updating 2021 Full Year Financial Outlook, Including Raising Adjusted EBITDA and Adjusted EPS Guidance. For further ...
‒ Q3 2021 Net Revenue of $529 million; GAAP Net Loss of $(4) million; Diluted Loss per Share of $(0.03) ‒ ‒ Adjusted EBITDA (1) of $135 million; Adjusted Diluted EPS (1) of $0.21 ‒ ‒ Updating 2021 Full Year Financial Outlo...
Amneal Pharmaceuticals (NYSE:AMRX) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is $0.20 (+25.0% Y/Y) and the consensus Revenue Estimate is $544.08M (+4.8% Y/Y). Over the last 2 years, AMRX has beaten EPS estimates 88%...
Reinforcing its commitment to purpose-driven strategy, performance, and culture Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its inaugural Corporate Responsibility Report with primarily 2020 data...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA). Dexamethas...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...